Gudbeta 25 Tablet contains Metoprolol Succinate 25 mg, a cardioselective beta-1 adrenergic receptor blocker primarily indicated for the management of hypertension, angina pectoris, and heart failure. By selectively inhibiting beta-1 receptors in the heart, Metoprolol Succinate reduces heart rate, myocardial contractility, and cardiac output, thereby lowering blood pressure and decreasing myocardial oxygen demand. This extended-release formulation ensures a consistent therapeutic effect over 24 hours, improving patient compliance with once-daily dosing. Gudbeta 25 is also utilized in the secondary prevention of myocardial infarction and in controlling arrhythmias. It is contraindicated in patients with severe bradycardia, heart block greater than first degree without a pacemaker, cardiogenic shock, and decompensated heart failure. Caution is advised in patients with asthma, diabetes mellitus, and peripheral vascular disease. Common adverse effects include fatigue, dizziness, hypotension, and gastrointestinal disturbances. Dose adjustments may be necessary in renal or hepatic impairment. Gudbeta 25 should be administered under medical supervision with regular monitoring of blood pressure, heart rate, and cardiac function. Abrupt discontinuation should be avoided to prevent exacerbation of angina or precipitating myocardial infarction. This medication is an integral component of cardiovascular disease management, contributing to improved morbidity and mortality outcomes.